Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that its CEO and Chairman, John Yu, MD, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The event will take place from Sept. 14-16, 2026, at the Lotte New York Palace Hotel. This presentation is expected to draw attention from investors and industry experts keen on advancements in oncology therapeutics.
The company is based in Los Angeles, California, and is at the forefront of using structural biology to address drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This approach could significantly impact treatment paradigms for patients who currently have limited options due to resistance.
The significance of this announcement lies in the potential of ENV-105 to address a major challenge in oncology: drug resistance. Many cancers eventually become resistant to standard treatments, leading to relapse and poorer outcomes. If successful, ENV-105 could be a game-changer, offering a way to sensitize tumors to existing therapies and improve patient survival. The presentation at the H.C. Wainwright conference provides a platform for the company to showcase its science and clinical progress to a wide audience of investors and potential partners.
For more information about Kairos Pharma, visit the company's newsroom at https://ibn.fm/KAPA. The full press release is available at https://ibn.fm/NrBQD.
As a clinical-stage company, Kairos Pharma's progress will be closely watched by the medical and investment communities. The H.C. Wainwright conference is a well-known venue for biotech companies to present their latest developments, and Kairos Pharma's participation underscores its commitment to advancing its pipeline. The outcome of ENV-105's clinical trials could have far-reaching implications for cancer treatment, potentially offering new hope for patients with resistant tumors.
